A detailed history of Northern Trust Corp transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 108,678 shares of CCCC stock, worth $502,092. This represents 0.0% of its overall portfolio holdings.

Number of Shares
108,678
Previous 108,677 -0.0%
Holding current value
$502,092
Previous $614,000 44.46%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$5.3 - $11.0 $5 - $11
1 Added 0.0%
108,678 $887,000
Q4 2023

Feb 13, 2024

BUY
$1.18 - $6.03 $20,868 - $106,640
17,685 Added 19.44%
108,677 $614,000
Q3 2023

Nov 13, 2023

SELL
$1.81 - $3.89 $300 - $645
-166 Reduced 0.18%
90,992 $169,000
Q2 2023

Aug 11, 2023

SELL
$2.75 - $3.77 $806,976 - $1.11 Million
-293,446 Reduced 76.3%
91,158 $250,000
Q1 2023

May 15, 2023

SELL
$3.1 - $9.02 $44,726 - $130,140
-14,428 Reduced 3.62%
384,604 $1.21 Million
Q4 2022

Feb 13, 2023

BUY
$5.42 - $10.24 $92,405 - $174,581
17,049 Added 4.46%
399,032 $2.35 Million
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $92,047 - $146,382
11,463 Added 3.09%
381,983 $3.35 Million
Q2 2022

Aug 12, 2022

BUY
$5.06 - $26.46 $107,565 - $562,486
21,258 Added 6.09%
370,520 $2.79 Million
Q1 2022

May 13, 2022

SELL
$19.99 - $33.23 $248,555 - $413,181
-12,434 Reduced 3.44%
349,262 $8.47 Million
Q4 2021

Feb 08, 2022

SELL
$29.39 - $46.86 $66,333 - $105,763
-2,257 Reduced 0.62%
361,696 $11.6 Million
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $2.18 Million - $3.06 Million
60,574 Added 19.97%
363,953 $16.3 Million
Q2 2021

Aug 13, 2021

BUY
$30.39 - $42.18 $5.6 Million - $7.77 Million
184,303 Added 154.78%
303,379 $11.5 Million
Q1 2021

May 12, 2021

SELL
$31.96 - $46.5 $191,568 - $278,721
-5,994 Reduced 4.79%
119,076 $4.41 Million
Q4 2020

Feb 11, 2021

BUY
$22.8 - $37.05 $2.85 Million - $4.63 Million
125,070 New
125,070 $4.14 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $226M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.